about
Current and emerging treatments for vitiligo.New discoveries in the pathogenesis and classification of vitiligo.The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo.Diversity in the dermatology workforce.Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference.Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne.Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo.Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd.Increasing racial and ethnic diversity in dermatology: A call to action.Cultural competence for the 21st century dermatologist practicing in the United States.Time for a patient-oriented outcome in vitiligo: the vitiligo noticeability scale.Quality of life in patients with vitiligo using the Short Form-36.A cross-sectional, comparative study of home vs in-office NB-UVB phototherapy for vitiligo.Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.The Importance of Patient Registries in Skin of Color.The majority of patients presenting with vitiligo have a clinical sign of activity.Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.Use of Suction Blisters for Noncultured Epidermal Suspension Grafting in Patients With Vitiligo.International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentationAddition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligoSuccessful treatment with narrowband ultraviolet B phototherapy of burn-induced leucodermaAssociation of Quality of Life and Location of Lesions in Patients With VitiligoA Missed Opportunity to Discuss Racial and Gender Bias in DermatologyInterpretability of the Modified Melasma Area and Severity Index (mMASI)
P50
Q36406814-08BA50BC-F804-4AA3-88F5-90AA3672A117Q38670498-13A1CF70-185B-4464-9BF2-EBD377F9C464Q38755560-093F5EF1-3381-4FF4-8E2C-D009CA7D4AEDQ38787169-8FEEFB28-7A5B-406E-ABFE-C1FE26625D36Q38793388-FE97E62F-E4F5-469D-B4D0-7B4E4E48499DQ38843486-872671CB-BB71-4BD3-878F-BC114F9140D9Q39187034-B2A6902A-C027-44F7-AF2F-6A1031E96C59Q40256899-3991A608-D407-4370-AF59-07409C6928F0Q45961818-A64B3690-EA26-4799-BB44-5DCDE29C7677Q46047512-955398E5-4593-454B-92FA-CC9F8E861CA4Q47826853-34827164-B491-4665-892C-8CCBBC77DA1EQ48129347-CCC5E43D-DA84-4EC3-B2C8-6A536D7ED73DQ48204038-B26F2608-3744-44C7-94DE-66FF5C568853Q49507679-01F86FCD-49FB-4A1D-B646-A242505CF3B3Q49895259-E7FE38D1-F7E3-456F-A7C6-2673B2349E0DQ50058529-07114928-9794-44EF-9A35-24113367D4BEQ51448115-58382D42-CED9-43FB-A34B-009890AAA45FQ54372751-6E573D8B-61A3-47D0-AD14-DE5EDF82B498Q62660841-9A5CF9AA-8A61-4BEC-B7ED-E058B89CE19EQ62660843-4AC49710-1DEF-41FD-B2B3-29CE11F26935Q62660845-87F2E25E-2D3A-4C72-AC3D-7E1152A7F618Q62660848-EEFBA53D-E691-47BC-8060-4CC191493370Q62660850-01A15883-6769-4E4D-9160-4D750A6AD5D8Q62660852-E0FC99D9-D50D-4801-974D-D97816FF4699
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amit G Pandya
@ast
Amit G Pandya
@en
Amit G Pandya
@es
Amit G Pandya
@nl
Amit G Pandya
@sl
type
label
Amit G Pandya
@ast
Amit G Pandya
@en
Amit G Pandya
@es
Amit G Pandya
@nl
Amit G Pandya
@sl
prefLabel
Amit G Pandya
@ast
Amit G Pandya
@en
Amit G Pandya
@es
Amit G Pandya
@nl
Amit G Pandya
@sl
P106
P21
P31
P496
0000-0002-3916-2651
P569
2000-01-01T00:00:00Z